Antibiotic Resistance Mechanisms
A Step 1 high-yield microbiology lesson on antibiotic resistance mechanisms, organizing the four core strategies (enzymatic inactivation, target modification, reduced uptake/efflux, and pathway bypass) around the exam's favorite organisms — MRSA, VRE, ESBL/CRE, and resistant pneumococcus — with buzzword vignettes, a comparison table, and the β-lactam resistance ladder.
Overview: How Bacteria Defeat Antibiotics
Antibiotic resistance is a high-yield, integrative Step 1 topic that ties microbiology to pharmacology. Almost every mechanism the boards test falls into one of four buckets:
- Enzymatic inactivation of the drug — the bug makes an enzyme that chews up the antibiotic (e.g., β-lactamases hydrolyze the β-lactam ring; aminoglycoside-modifying enzymes acetylate/phosphorylate/adenylate the drug).
- Modification of the drug's target — the binding site is altered so the drug no longer sticks (e.g., MRSA's altered PBP2a, VRE's D-Ala-D-Lactate cell-wall terminus, ribosomal methylation by erm against macrolides, DNA gyrase mutations against fluoroquinolones).
- Decreased intracellular drug concentration — porin loss (reduced influx) or efflux pumps (active export of tetracyclines, fluoroquinolones).
- Bypass / overproduction of the target pathway — sulfonamide/trimethoprim resistance via altered or overproduced folate enzymes.
Resistance genes spread horizontally on plasmids via conjugation (the dominant route on exams), plus transposons and transformation — which is why an entire ICU can share the same resistant Klebsiella.
- MRSA = mecA gene → altered penicillin-binding protein (PBP2a) with low affinity for β-lactams; confers resistance to ALL β-lactams except the anti-MRSA cephalosporins ceftaroline (and ceftobiprole). β-lactamase inhibitors do NOT help (it is not an enzyme problem).
- VRE = vanA operon → terminal D-Ala-D-Ala changed to D-Ala-D-Lactate, dropping vancomycin binding ~1000-fold.
- β-lactamase (penicillinase) hydrolyzes the β-lactam ring; escalating versions: penicillinase → ESBL (kills 3rd-gen cephalosporins + aztreonam) → carbapenemase (KPC, NDM-1).
- Aminoglycoside resistance = bacterial transferase enzymes (acetyl-, phospho-, adenylyl-transferase) that chemically modify the drug.
- Fluoroquinolone resistance = mutation in DNA gyrase / topoisomerase IV ± efflux pumps.
- Macrolide resistance = erm-encoded methylase modifies 23S rRNA of the 50S subunit (MLSB resistance) ± mef efflux.
- Sulfonamide resistance = altered dihydropteroate synthase or PABA overproduction; trimethoprim = altered dihydrofolate reductase.
- Vancomycin has no activity against gram-negatives (intrinsic resistance — the molecule is too large to cross the outer membrane).
- Enterococcus is intrinsically resistant to cephalosporins — never treat enterococcal infection with a cephalosporin.
Vignette: A hemodialysis patient with nasal colonization develops a purulent skin abscess; culture grows gram-positive cocci in clusters, catalase-positive, coagulase-positive, and is resistant to oxacillin/cefoxitin. → Organism/mechanism: MRSA — mecA → PBP2a. → Treatment: Vancomycin (IV); alternatives linezolid, daptomycin, ceftaroline. (Community MRSA → TMP-SMX, doxycycline, or clindamycin.)
Vignette: An ICU patient on prolonged vancomycin develops bacteremia; blood grows gram-positive cocci in pairs/chains, catalase-negative, PYR-positive, grows in bile + 6.5% NaCl, and is vancomycin-resistant. → Organism/mechanism: VRE (Enterococcus) — vanA, D-Ala-D-Lactate. → Treatment: Linezolid or daptomycin (avoid daptomycin for pneumonia — it is inactivated by pulmonary surfactant).
Vignette: A patient with a UTI grows E. coli/*Klebsiella* that is resistant to ceftriaxone but susceptibility is restored by clavulanate. → Organism/mechanism: ESBL producer (extended-spectrum β-lactamase). → Treatment: Carbapenem (meropenem, ertapenem).
Resistance Comparison Table
| Organism / Phenotype | Key resistance mechanism | Setting / disease | Treatment |
|---|---|---|---|
| MRSA | mecA → PBP2a (low-affinity PBP) | Skin/soft tissue, bacteremia, pneumonia | Vancomycin; linezolid, daptomycin, ceftaroline |
| MSSA (penicillinase +) | β-lactamase (blaZ) hydrolyzes ring | Same infections, sensitive strain | Nafcillin/oxacillin, cefazolin |
| VRE (Enterococcus) | vanA: D-Ala-D-Ala → D-Ala-D-Lactate | Nosocomial bacteremia, UTI, endocarditis | Linezolid or daptomycin (not for lung) |
| Pen-resistant *S. pneumoniae* | Altered PBP | Meningitis, pneumonia, otitis media | High-dose amoxicillin/ceftriaxone; meningitis → vanc + ceftriaxone |
| ESBL E. coli / *Klebsiella* | Extended-spectrum β-lactamase | UTI, bacteremia | Carbapenem |
| CRE / KPC *Klebsiella* | Carbapenemase (KPC serine; NDM-1 metallo) | ICU, multidrug-resistant infection | Ceftazidime-avibactam; polymyxins (colistin) |
| SPACE organisms (Pseudomonas, Enterobacter…) | Inducible AmpC β-lactamase | Nosocomial infection | Cefepime or carbapenem (avoid 3rd-gen ceph) |
Boards love escalating β-lactam resistance — know what each step destroys and what still works:
- Penicillinase (narrow β-lactamase): destroys penicillin G, ampicillin. Overcome with penicillinase-resistant penicillins (nafcillin/oxacillin) or β-lactamase-inhibitor combos (amoxicillin-clavulanate).
- ESBL: destroys penicillins, cephalosporins (especially 3rd-gen; cefepime is unreliable), and aztreonam; spares carbapenems and cephamycins. Inhibited in vitro by clavulanate, but clinically treat with a carbapenem.
- AmpC (inducible, chromosomal): in SPACE organisms; NOT inhibited by clavulanate; hydrolyzes cephamycins → use cefepime or a carbapenem.
- Carbapenemase (KPC, NDM-1): destroys carbapenems too → ceftazidime-avibactam (KPC, a serine enzyme), colistin/polymyxins for metallo-β-lactamases such as NDM-1 (avibactam does not cover metallo enzymes).
- Altered PBP (MRSA, resistant pneumococcus): an enzyme inhibitor cannot help because there is no enzyme to inhibit — the target itself changed. Ceftaroline is the anti-MRSA β-lactam that binds PBP2a; otherwise vancomycin.
- β-lactamase inhibitors = "CAST" → Clavulanic acid, Avibactam, Sulbactam, Tazobactam. (All four block β-lactamases; avibactam also covers KPC serine carbapenemases but not metallo-β-lactamases.)
- Inducible AmpC (chromosomal cephalosporinase) organisms = "SPACE" → Serratia, Pseudomonas, Acinetobacter, Citrobacter, Enterobacter (avoid 3rd-gen cephalosporins — they can derepress AmpC and select resistance mid-treatment).
- Aminoglycoside-modifying enzymes — remember the three transferases: acetyl-, phospho-, adenylyl (nucleotidyl)-transferase.
- VRE terminus swap: vanA changes the cell-wall terminus from D-Ala-D-Ala to D-Ala-D-Lactate. Memory hook: resistance trades the last Alanine for Lactate (Ala → Lac), so vancomycin can no longer grip the stem peptide (~1000× lower affinity).
Vignette: A ventilated ICU patient grows *Klebsiella* resistant to carbapenems; the lab reports a KPC carbapenemase. → Mechanism: CRE (carbapenem-resistant Enterobacteriaceae) via serine carbapenemase. → Treatment: Ceftazidime-avibactam; polymyxins/colistin as salvage.
Vignette: A child with meningitis grows *S. pneumoniae* with a high penicillin MIC and no β-lactamase detected. → Mechanism: Altered PBP (transformation-acquired) — not a β-lactamase, so inhibitor combos are useless. → Treatment: Empiric vancomycin + ceftriaxone for pneumococcal meningitis.
Vignette: A patient on a macrolide for Streptococcus fails therapy; the isolate is erythromycin-resistant with inducible clindamycin resistance (positive D-test). → Mechanism: erm-encoded ribosomal methylase modifying 23S rRNA (MLSB resistance). → Treatment: Use an agent outside the MLS class (e.g., an appropriate β-lactam or vancomycin per susceptibilities); a positive D-test means avoid clindamycin.
Practice Microbiology now
Board-style questions, spaced-repetition flashcards, and a Socratic AI tutor — free to start.